Latest News and Press Releases

Oral presentation at AASLD highlights broad clinical activity of Chemomab’s CM-101 across multiple biomarkers and its disease-modifying potential in PSC

In 3Q reported positive CM-101 PSC Ph 2 results. On track for 2 milestones in Q125--FDA agreement on PSC Ph 3 design and Ph 2 open label extension readout.

Chemomab will report 3Q 2024 financial results and provide a corporate update on November 14, 2024 at 7am ET.

Chemomab announces late-breaking oral presentation of CM-101 Phase 2 results in primary sclerosing cholangitis patients at 2024 AASLD The Liver Meeting

Chemomab will participate in the ROTH Healthcare Opportunities Conference in NYC on Oct 9 and the Maxim Healthcare Virtual Summit on Oct 16 at 9am ET.

Chemomab will be presenting at the HC Wainwright Global Investment Conference and the HBM Biopharma Summit in September

Ph 2 PSC data showed safety/activity supporting advancing CM-101 to Ph 3. New financing extends cash runway to early 2026. 2 milestones on track for 1Q25.

Chemomab will report its second quarter 2024 financial results and provide a business update on August 21, 2024 at 7:00am ET.

Chemomab closed a $10 million PIPE financing that included new and existing top tier investors and extends the cash runway through the beginning of 2026

Chemomab has regained full compliance with the Nasdaq minimum bid price rule